Wearable, smartphone-controlled, rechargeable device effective for reducing voiding frequency; is safe in overactive bladder
TUESDAY, April 2, 2024 (HealthDay News) — For patients with overactive bladder (OAB) symptoms, a wearable, smartphone-controlled, rechargeable transcutaneous tibial nerve stimulation (TTNS) device is efficacious and safe, according to a study published online March 11 in BJU International.
Limin Liao, M.D., Ph.D., from the China Rehabilitation Science Institute in Beijing, and colleagues conducted a prospective, randomized clinical trial involving eligible patients with OAB symptoms who were randomly assigned to a TTNS or sham group.
The researchers found that the mean change of voiding frequency/24 hours at four weeks was −3.5 and −0.6 in the stimulation and sham groups, respectively, in the full analysis set. The results were similar in the per-protocol set (−3.5 versus −0.4, respectively). Micturition volume/void significantly improved at four weeks in both the full analysis set and per-protocol set. The improvement in patient perception of bladder condition was almost significant in the full analysis set and was significant in the per-protocol set. The American Urological Association Symptom Index Quality of Life Score improved significantly in both groups in the full analysis and per-protocol sets; no significant differences were seen in urgency score/void, nocturia episodes/day, or overactive bladder symptom score. There were no reports of device-related serious adverse events.
“TTNS using the novel, wearable, smartphone-controlled, rechargeable, and ambulatory TTNS device is effective and safe for treating OAB,” the authors write. “This approach could be a new potential home-based treatment modality.”
Abstract/Full Text (subscription or payment may be required)
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Better Cardiovascular Health Inversely Linked to Overactive Bladder
Family History of CRC Increases CRC Risk Similarly in IBD, General Population
People With ADHD Experience 50 Percent More GI Symptoms
Relapse Rare After Appendiceal Adenocarcinoma Resection
Bowel Urgency in Ulcerative Colitis Linked to Disease-Related Disability
1 in 4 Former NFL Players Had CTE at Death in 2016 to 2021
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy